Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | GCK | P35557 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.35 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | PRCP | P42785 | 1/20 | 0.35 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7824370 | 0.70 | LMNA (0.43) | LMNABLMALOX15GCKCYP3A4 | |
| SCHEMBL6838308 | 0.70 | CYP3A4 (0.40) | ALOX15CYP3A4CYP2D6MEN1KMT2A | |
| SCHEMBL3455254 | 0.69 | CYP3A4 (0.42) | ALOX15CYP3A4CYP2D6MEN1KMT2A | |
| Acetic Acid SCHEMBL28943323 | 0.68 | LMNA (0.41) | LMNABLMALOX15CYP3A4CYP2D6 | |
| Benzene SCHEMBL28485309 | 0.67 | SIGMAR1 (0.44) | ALOX15CYP3A4CYP2D6MEN1KMT2A | |
| SCHEMBL9054248 | 0.66 | KDM1A (0.45) | ALOX15CYP3A4CYP2D6MEN1KMT2A | |
| SCHEMBL28893830 | 0.66 | CYP3A4 (0.37) | ALOX15CYP3A4CYP2D6MEN1KMT2A | |
| SCHEMBL6985972 | 0.66 | CYP3A4 (0.42) | ALOX15CYP3A4CYP2D6MEN1KMT2A | |
| SCHEMBL414650 | 0.65 | CYP3A4 (0.44) | ALOX15CYP3A4CYP2D6MEN1KMT2A | |
| Phthalic Acid SCHEMBL22471697 | 0.63 | ALDH1A1 (0.64) | ALOX15ALDH1A1MEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080004226-A1 | Combination of FBPase Inhibitors and Insulin Sensitizers for the Treatment of Diabetes | METABASIS THERAPEUTICS, INC. (US) | 2008-01-03 | — | — | US | disclosed |
| EP-1143955-B1 | A COMBINATION OF FBPase INHIBITORS AND INSULIN SENSITIZERS FOR THE TREATMENT OF DIABETES | METABASIS THERAPEUTICS INC (US) | 2005-07-27 | — | — | EP | disclosed |
| EP-1552850-A2 | A combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes | Metabasis Therapeutics, Inc. (US) | 2005-07-13 | — | — | EP | disclosed |
| US-20040167178-A1 | Combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes | ERION MARK D (US) | 2004-08-26 | — | — | US | disclosed |
| US-6756360-B1 | PHOSPHONATE, PHOSPHATE AND BISAMINO PHOSPHONATE DERIVATIVES | METABASIS THERAPEUTICS, INC. | 2004-06-29 | — | — | US | disclosed |
| EP-1143955-A3 | A COMBINATION OF FBPase INHIBITORS AND INSULIN SENSITIZERS FOR THE TREATMENT OF DIABETES | Metabasis Therapeutics Inc. (US) | 2002-08-28 | — | — | EP | disclosed |
| EP-1143955-A2 | A COMBINATION OF FBPase INHIBITORS AND INSULIN SENSITIZERS FOR THE TREATMENT OF DIABETES | Metabasis Therapeutics Inc. (US) | 2001-10-17 | — | — | EP | disclosed |
| WO-2000038666-A2 | A COMBINATION OF FBPase INHIBITORS AND INSULIN SENSITIZERS FOR THE TREATMENT OF DIABETES | METABASIS THERAPEUTICS, INC. (US) | 2000-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167178-A1 | Combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes | FBP1, G6PC1, IRS1 | LMNA 3824/4885BLM 2235/4885ALOX15 4064/4885 |
| US-20080004226-A1 | Combination of FBPase Inhibitors and Insulin Sensitizers for the Treatment of Diabetes | FBP1, G6PC1, IRS1 | LMNA 3824/4885BLM 2235/4885ALOX15 4064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.